Floret

/ Dexcel

Regular daily intake of tablets for 21 consecutive days is important for the preservation of contraceptive efficacy. Tablets must be taken in the order directed on the package every day at about the same time with some liquid as needed.
One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval during which time a withdrawal bleed occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started.
Please refer to the license holder for further details.

Oral Contraceptive.

– Hypersensitivity to the active substances or to any of the excipients.
– Presence or risk of venous thromboembolism (VTE)
• Thrombophlebitis or venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]) or other diseases, associated with an increased thromboembolic risk such as thrombogenic valvulopathies and thrombogenic rhythm disorders (current or history).
• Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
• Major surgery with prolonged immobilization.
• A high risk of venous thromboembolism due to the presence of multiple risk factors
– Presence or risk of arterial thromboembolism (ATE)
• Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris)
• Cerebrovascular or coronary artery disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA)
• Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant)
• History of migraine with focal neurological symptoms
• A high risk of arterial thromboembolism due to multiple risk factors or to the presence of one serious risk factor such as:
Diabetes mellitus with vascular symptoms
Severe hypertension
Severe dyslipoproteinaemia
– Known or suspected carcinoma of the breast
– Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
– Undiagnosed abnormal vaginal bleeding
– Hepatic adenomas or carcinomas, or acute or chronic liver disease, as long as liver function has not returned to normal
– Pancreatitis associated with severe hypertriglyceridemia (current or history)
– Known or suspected pregnancy
-Medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir or medicinal products containing glecaprevir/pibrentasvir.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

This medicinal product contains sucrose.